Cns Pharmaceuticals Stock Analysis

CNSP Stock  USD 2.37  0.51  17.71%   
Cns Pharmaceuticals is overvalued with Real Value of 1.39 and Target Price of 0.5. The main objective of Cns Pharmaceuticals stock analysis is to determine its intrinsic value, which is an estimate of what Cns Pharmaceuticals is worth, separate from its market price. There are two main types of Cns Pharmaceuticals' stock analysis: fundamental analysis and technical analysis.
The Cns Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cns Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Cns Stock trading window is adjusted to America/New York timezone.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

Cns Stock Analysis Notes

The company has price-to-book (P/B) ratio of 1.29. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cns Pharmaceuticals recorded a loss per share of 352.97. The entity had not issued any dividends in recent years. The firm had 1:50 split on the 5th of June 2024. CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company was incorporated in 2017 and is based in Houston, Texas. Cns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people. For more info on Cns Pharmaceuticals please contact JD Esq at 800 946 9185 or go to https://www.cnspharma.com.

Cns Pharmaceuticals Investment Alerts

Cns Pharmaceuticals generated a negative expected return over the last 90 days
Cns Pharmaceuticals has high historical volatility and very poor performance
Cns Pharmaceuticals has a very high chance of going through financial distress in the upcoming years
Net Loss for the year was (18.85 M) with profit before overhead, payroll, taxes, and interest of 0.
Cns Pharmaceuticals currently holds about 8.96 M in cash with (14.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22.
Cns Pharmaceuticals has a poor financial position based on the latest SEC disclosures
Latest headline from thelincolnianonline.com: Title CNS Pharmaceuticals Announces Release of Latest Corporate Updates in New 8-K Filing

Cns Pharmaceuticals Upcoming and Recent Events

1st of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

Cns Largest EPS Surprises

Earnings surprises can significantly impact Cns Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-11-13
2024-09-30-0.1-0.2527-0.1527152 
2023-11-13
2023-09-30-2.4-2.7-0.312 
2022-11-10
2022-09-30-2.4-2.7-0.312 
View All Earnings Estimates

Cns Pharmaceuticals Environmental, Social, and Governance (ESG) Scores

Cns Pharmaceuticals' ESG score is a quantitative measure that evaluates Cns Pharmaceuticals' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cns Pharmaceuticals' operations that may have significant financial implications and affect Cns Pharmaceuticals' stock price as well as guide investors towards more socially responsible investments.

Cns Stock Institutional Investors

Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bank Of America Corp2024-12-31
440
Sbi Securities Co Ltd2024-12-31
105
Synergy Investment Management, Llc2024-12-31
9.0
Wells Fargo & Co2024-12-31
4.0
Global Retirement Partners, Llc.2024-09-30
2.0
Parallel Advisors, Llc2024-09-30
0.0
Tower Research Capital Llc2024-12-31
0.0
Northern Trust Investments N A2024-12-31
0.0
Fmr Inc2024-09-30
0.0
Jane Street Group Llc2024-12-31
419.7 K
Geode Capital Management, Llc2024-12-31
387.1 K
Note, although Cns Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cns Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.28 M.

Cns Profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(12.75)(12.11)
Return On Capital Employed 4.89  5.14 
Return On Assets(12.75)(12.11)
Return On Equity 4.89  3.37 

Management Efficiency

Cns Pharmaceuticals has return on total asset (ROA) of (2.24) % which means that it has lost $2.24 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.1878) %, meaning that it created substantial loss on money invested by shareholders. Cns Pharmaceuticals' management efficiency ratios could be used to measure how well Cns Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/26/2025, Return On Capital Employed is likely to grow to 5.14, though Return On Tangible Assets are likely to grow to (12.11). As of 02/26/2025, Total Current Liabilities is likely to grow to about 7.4 M, while Liabilities And Stockholders Equity is likely to drop slightly above 1.9 M.
Last ReportedProjected for Next Year
Book Value Per Share(67.96)(64.56)
Tangible Book Value Per Share(67.96)(64.56)
Enterprise Value Over EBITDA(11.35)(11.92)
Price Book Value Ratio(48.35)(50.77)
Enterprise Value Multiple(11.35)(11.92)
Price Fair Value(48.35)(50.77)
Leadership at Cns Pharmaceuticals emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Beta
1.049
Return On Assets
(2.24)
Return On Equity
(10.19)

Technical Drivers

As of the 26th of February, Cns Pharmaceuticals shows the Mean Deviation of 5.08, standard deviation of 8.25, and Risk Adjusted Performance of (0.08). Cns Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cns Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was nineteen with a total number of output elements of fourty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cns Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cns Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Cns Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Gumulka Jerzy over a week ago
Acquisition by Gumulka Jerzy of 17500 shares of Cns Pharmaceuticals subject to Rule 16b-3
 
Gumulka Jerzy over three months ago
Acquisition by Gumulka Jerzy of 2500 shares of Cns Pharmaceuticals at 1.7 subject to Rule 16b-3
 
Charles Faith L. over three months ago
Acquisition by Charles Faith L. of 3500 shares of Cns Pharmaceuticals subject to Rule 16b-3
 
Downs Christopher over three months ago
Acquisition by Downs Christopher of 4500 shares of Cns Pharmaceuticals at 1.1537 subject to Rule 16b-3
 
Cortice Biosciences, Inc. over six months ago
Disposition of tradable shares by Cortice Biosciences, Inc. of Cns Pharmaceuticals subject to Rule 16b-3
 
Downs Christopher over six months ago
Acquisition by Downs Christopher of 142000 shares of Cns Pharmaceuticals at 2.04 subject to Rule 16b-3
 
Charles Faith L. over six months ago
Acquisition by Charles Faith L. of 17500 shares of Cns Pharmaceuticals at 0.2586 subject to Rule 16b-3
 
Charles Faith L. over six months ago
Acquisition by Charles Faith L. of 17500 shares of Cns Pharmaceuticals at 0.2586 subject to Rule 16b-3
 
Climaco John M over a year ago
Purchase by Climaco John M of 166666 shares of Cns Pharmaceuticals
 
Andraczke Andrzej over a year ago
Acquisition by Andraczke Andrzej of 68961 shares of Cns Pharmaceuticals subject to Rule 16b-3
 
Downs Christopher over a year ago
Purchase by Downs Christopher of 27000 shares of Cns Pharmaceuticals
 
Climaco John M over a year ago
Purchase by Climaco John M of 2750 shares of Cns Pharmaceuticals

Cns Pharmaceuticals Outstanding Bonds

Cns Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cns Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cns bonds can be classified according to their maturity, which is the date when Cns Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Cns Pharmaceuticals Predictive Daily Indicators

Cns Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cns Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Cns Pharmaceuticals Corporate Filings

8K
21st of February 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of January 2025
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
11th of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
8K
3rd of December 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
15th of November 2024
Other Reports
ViewVerify
13A
14th of November 2024
An amended filing to the original Schedule 13G
ViewVerify
8K
1st of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
28th of October 2024
Other Reports
ViewVerify

Cns Pharmaceuticals Forecast Models

Cns Pharmaceuticals' time-series forecasting models are one of many Cns Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cns Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Cns Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cns Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cns shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cns Pharmaceuticals. By using and applying Cns Stock analysis, traders can create a robust methodology for identifying Cns entry and exit points for their positions.
Last ReportedProjected for Next Year

Current Cns Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cns analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cns analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
0.5Buy1Odds
Cns Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Cns analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cns stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cns Pharmaceuticals, talking to its executives and customers, or listening to Cns conference calls.
Cns Analyst Advice Details

Cns Stock Analysis Indicators

Cns Pharmaceuticals stock analysis indicators help investors evaluate how Cns Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cns Pharmaceuticals shares will generate the highest return on investment. By understating and applying Cns Pharmaceuticals stock analysis, traders can identify Cns Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow10.1 M
Common Stock Shares Outstanding75.3 K
Total Stockholder Equity-4.4 M
Property Plant And Equipment Net4933.00
Cash And Short Term Investments548.7 K
Cash548.7 K
Accounts Payable5.8 M
Net Debt-247.9 K
50 Day M A0.1331
Total Current Liabilities6.1 M
Other Operating Expenses18.9 M
Non Current Assets Total109.7 K
Non Currrent Assets Other104.8 K
Stock Based CompensationM

Additional Tools for Cns Stock Analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.